Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Inclusion Criteria: * • Written informed consent has been obtained * Males and females, at least 18 years of age * History of IC/PBS for at least 6 months documented in the medical record * Recurring IC/PBS symptoms * An average of 8 or more urine voids over a 3-day period, confirmed by the baseline voiding diary * Bladder pain score \> 4 in the last 24 hours (assessed at screening visit) * Previous use of medications and/or treatment(s) for symptom relief * Females of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives (birth control pills)) during the 4 week course of therapy and 1 week thereafter * Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the voiding diaries and self-administered questionnaires Exclusion Criteria: * • Subjects currently taking prescribed medications for IC/PBS will be able to continue the medications throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded. * Subjects must not have had intravesical treatment(s)/bladder installations of the following medications: dimethylsulfoxide (DMSO), lidocaine and/or heparin within 1 month prior to study visit 1 * Pregnant or lactating * History of bleeding diathesis * Currently on anticoagulant therapy (e.g. warfarin, clopidogrel) * Active bleeding peptic ulcer disease * Obvious neurological impairment which may be affecting bladder function * Known allergy to liposomes and/or egg yolk * Current or previous participation in another therapeutic or device study within 6 months of the screening visit * The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study